Active Filter(s):
Details:
Under the terms of the license and collaboration agreement, Xbiome acquires exclusive development and commercial rights for all human use to Aurealis clinical stage DFU drug candidate AUP-16 in Mainland China, Hong Kong, Macao, and Taiwan.
Lead Product(s): AUP-16
Therapeutic Area: Podiatry Product Name: AUP-16
Highest Development Status: Phase I/ Phase II Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Xbiome
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration January 28, 2022